Manager × security

BML Capital Management, LLC ORMP holdings history

ORAMED PHARMACEUTICALS INC · CUSIP 68403P203 · CIK 1616824

This is the oldest quarter open without an account, so changes against the quarter before it are withheld. Sign in to see them.
Citable facts

As of 2026-06-30, BML Capital Management, LLC reported 866.27K ORMP (shares), valued at $4.17M, or 2.38% of its reported non-derivative portfolio. Filed 2026-08-07.

Verify history & sources →
Portfolio weight and quantity history
Reported portfolio weight
2.38%
Shares
866.27K
866,269
Reported value
$4.17M
USD

Shares decreased 72.65%; reported value decreased 61.31%, and weight changed -4.55 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.

Left: % · Right: Shares · Independently scaled axes

Exact data and methodology

Axes scale independently; a crossing does not mean equal values. Weight uses each quarter's total reported non-derivative value. Same CUSIP; missing quarters are gaps, not zero. Revised history may include later disclosures.

QuarterWeightQuantitySource
Q2 20262.38%866,269SEC filing ↗Filed Aug 7, 2026
Q1 20266.93%3,167,231SEC filing ↗Filed May 6, 2026
Q4 20257.99%3,167,231SEC filing ↗Filed Feb 3, 2026
Q3 20257.69%3,167,231SEC filing ↗Filed Nov 10, 2025
Q2 20255.32%3,083,253SEC filing ↗Filed Aug 11, 2025
Q1 20255.23%3,020,748SEC filing ↗Filed May 7, 2025
Q4 20243.97%2,643,907SEC filing ↗Filed Feb 7, 2025
Q3 20243.14%2,186,191SEC filing ↗Filed Nov 5, 2024
Q2 20242.54%1,349,038SEC filing ↗Filed Aug 7, 2024
Q1 20241.65%844,496SEC filing ↗Filed Apr 24, 2024Amended
Q4 20232.30%1,261,559SEC filing ↗Filed Feb 2, 2024Amended
Q3 20231.88%781,292SEC filing ↗Filed Oct 23, 2023

History & evidence by quarter

QuarterWeightQuantityValueChange explainedSource
Q3 20231.88%781,292$2.04MThe prior quarter is outside the free window. Sign in for the comparison.SEC filing ↗
Filed Oct 23, 2023
Q4 20232.30%1,261,559$2.91MShares increased 61.47%; reported value increased 42.91%, and weight changed +0.42 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 2, 2024
Q1 20241.65%844,496$2.47MShares decreased 33.06%; reported value decreased 15.38%, and weight changed -0.65 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Apr 24, 2024
Q2 20242.54%1,349,038$3.47MShares increased 59.74%; reported value increased 40.60%, and weight changed +0.89 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 7, 2024
Q3 20243.14%2,186,191$5.33MShares increased 62.06%; reported value increased 53.86%, and weight changed +0.60 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 5, 2024
Q4 20243.97%2,643,907$6.40MShares increased 20.94%; reported value increased 19.95%, and weight changed +0.83 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 7, 2025
Q1 20255.23%3,020,748$6.46MShares increased 14.25%; reported value increased 1.03%, and weight changed +1.26 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 7, 2025
Q2 20255.32%3,083,253$6.94MShares increased 2.07%; reported value increased 7.32%, and weight changed +0.09 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 11, 2025
Q3 20257.69%3,167,231$8.36MShares increased 2.72%; reported value increased 20.53%, and weight changed +2.37 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 10, 2025
Q4 20257.99%3,167,231$9.03MShares unchanged; reported value increased 7.95%, and weight changed +0.30 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 3, 2026
Q1 20266.93%3,167,231$10.77MShares unchanged; reported value increased 19.30%, and weight changed -1.06 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 6, 2026
Q2 20262.38%866,269$4.17MShares decreased 72.65%; reported value decreased 61.31%, and weight changed -4.55 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 7, 2026
BML Capital Management, LLC · ORAMED PHARMACEUTICALS INC

Take these holdings further.

This page includes 12 of 12 reported holdings. Sign in to look up the full history beyond 3 years, use advanced screening & filtering, download CSV, and get the complete set through the Akkru API.

  • Download CSV
  • Earlier quarters
  • Advanced screening & filtering
  • API & AI access
Already have an account?

+ New accounts get free API credits to explore data beyond ownership filings.

For AI agents & developers

The initial HTML of this page carries its exact data as script#research-data (JSON): values, units, scope, preview limits and SEC sources. Read it directly, no script or API key needed; script#research-access says what needs an account.

Without an account: the last 3 years, with the row caps stated on the page. A free account opens all history on file on these pages and the CSV of what a page shows. Rows beyond the caps and bulk retrieval go through the authenticated API / MCP.

MCP  https://api.akkrudata.ai/mcp

get_institutional_portfolio
{"cik":"1616824","quarter":"2026Q2","cusip":"68403P203"}

get_institutional_manager_history
{"cik":"1616824","page_size":100}

Connect to MCP with OAuth and follow the returned pagination. Credits and usage limits depend on the account.

MCP endpoint
https://api.akkrudata.ai/mcp
API / MCP documentation
/documents
llms.txt
/llms.txt
Sources, coverage & how to read this data

Figures are as reported to the SEC and merged with later amendments where Akkru could match them. Preview limits apply to what is listed, not to the totals, which come from the complete reported data. Nothing is zero-filled: a missing quarter or month is shown as missing.

13F reports quarter-end long positions in securities traded on US exchanges, filed by managers holding at least $100 million of such securities; it is not the manager's full portfolio, not assets under management, and value changes are not returns. Weights use the reported total value as denominator. Option rows show notional value, not premium or net exposure. Amendments are merged into the quarter when Akkru could match them.